![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PCCA |
Gene summary for PCCA |
![]() |
Gene information | Species | Human | Gene symbol | PCCA | Gene ID | 5095 |
Gene name | propionyl-CoA carboxylase subunit alpha | |
Gene Alias | PCCA | |
Cytomap | 13q32.3 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | P05165 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5095 | PCCA | AEH-subject2 | Human | Endometrium | AEH | 5.70e-08 | 4.16e-01 | -0.2525 |
5095 | PCCA | AEH-subject3 | Human | Endometrium | AEH | 5.59e-22 | 5.84e-01 | -0.2576 |
5095 | PCCA | AEH-subject4 | Human | Endometrium | AEH | 5.53e-23 | 7.60e-01 | -0.2657 |
5095 | PCCA | AEH-subject5 | Human | Endometrium | AEH | 1.68e-46 | 9.64e-01 | -0.2953 |
5095 | PCCA | EEC-subject1 | Human | Endometrium | EEC | 3.90e-22 | 6.01e-01 | -0.2682 |
5095 | PCCA | EEC-subject2 | Human | Endometrium | EEC | 3.62e-13 | 4.75e-01 | -0.2607 |
5095 | PCCA | EEC-subject3 | Human | Endometrium | EEC | 1.05e-06 | 2.86e-01 | -0.2525 |
5095 | PCCA | EEC-subject4 | Human | Endometrium | EEC | 2.48e-27 | 6.75e-01 | -0.2571 |
5095 | PCCA | EEC-subject5 | Human | Endometrium | EEC | 7.64e-22 | 6.23e-01 | -0.249 |
5095 | PCCA | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.20e-03 | -1.06e-02 | -0.1869 |
5095 | PCCA | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.14e-03 | -9.50e-02 | -0.1875 |
5095 | PCCA | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.73e-04 | 3.42e-02 | -0.1883 |
5095 | PCCA | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 7.00e-04 | -8.95e-05 | -0.1934 |
5095 | PCCA | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.13e-06 | -7.54e-02 | -0.1917 |
5095 | PCCA | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 8.06e-06 | -6.90e-02 | -0.1916 |
5095 | PCCA | NAFLD1 | Human | Liver | NAFLD | 6.04e-14 | 1.34e+00 | -0.04 |
5095 | PCCA | S41 | Human | Liver | Cirrhotic | 1.36e-02 | 6.18e-01 | -0.0343 |
5095 | PCCA | S43 | Human | Liver | Cirrhotic | 5.11e-09 | -2.01e-01 | -0.0187 |
5095 | PCCA | HCC1_Meng | Human | Liver | HCC | 5.91e-59 | -3.22e-01 | 0.0246 |
5095 | PCCA | HCC2_Meng | Human | Liver | HCC | 5.39e-18 | -4.04e-01 | 0.0107 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
GO:0009062 | Colorectum | AD | fatty acid catabolic process | 41/3918 | 100/18723 | 4.02e-06 | 1.09e-04 | 41 |
GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
GO:0072329 | Colorectum | AD | monocarboxylic acid catabolic process | 44/3918 | 122/18723 | 8.05e-05 | 1.28e-03 | 44 |
GO:0016054 | Colorectum | AD | organic acid catabolic process | 73/3918 | 240/18723 | 3.20e-04 | 3.81e-03 | 73 |
GO:0044242 | Colorectum | AD | cellular lipid catabolic process | 66/3918 | 214/18723 | 3.96e-04 | 4.50e-03 | 66 |
GO:0046395 | Colorectum | AD | carboxylic acid catabolic process | 70/3918 | 236/18723 | 9.06e-04 | 8.71e-03 | 70 |
GO:0046459 | Colorectum | AD | short-chain fatty acid metabolic process | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
GO:00442821 | Colorectum | SER | small molecule catabolic process | 87/2897 | 376/18723 | 5.31e-05 | 1.27e-03 | 87 |
GO:00090621 | Colorectum | SER | fatty acid catabolic process | 31/2897 | 100/18723 | 7.09e-05 | 1.61e-03 | 31 |
GO:00723291 | Colorectum | SER | monocarboxylic acid catabolic process | 34/2897 | 122/18723 | 3.27e-04 | 5.22e-03 | 34 |
GO:00442421 | Colorectum | SER | cellular lipid catabolic process | 51/2897 | 214/18723 | 8.60e-04 | 1.05e-02 | 51 |
GO:00160541 | Colorectum | SER | organic acid catabolic process | 53/2897 | 240/18723 | 4.04e-03 | 3.30e-02 | 53 |
GO:00066311 | Colorectum | SER | fatty acid metabolic process | 79/2897 | 390/18723 | 6.34e-03 | 4.56e-02 | 79 |
GO:00090622 | Colorectum | MSS | fatty acid catabolic process | 32/3467 | 100/18723 | 8.28e-04 | 8.67e-03 | 32 |
GO:00442822 | Colorectum | MSS | small molecule catabolic process | 94/3467 | 376/18723 | 9.85e-04 | 9.86e-03 | 94 |
GO:00066312 | Colorectum | MSS | fatty acid metabolic process | 95/3467 | 390/18723 | 2.20e-03 | 1.84e-02 | 95 |
GO:00723292 | Colorectum | MSS | monocarboxylic acid catabolic process | 35/3467 | 122/18723 | 3.97e-03 | 2.90e-02 | 35 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00280 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa00640 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
hsa00630 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa002801 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa006401 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
hsa006301 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
hsa012002 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa006402 | Colorectum | SER | Propanoate metabolism | 13/1580 | 32/8465 | 3.20e-03 | 2.12e-02 | 1.54e-02 | 13 |
hsa012003 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa006403 | Colorectum | SER | Propanoate metabolism | 13/1580 | 32/8465 | 3.20e-03 | 2.12e-02 | 1.54e-02 | 13 |
hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa002802 | Colorectum | MSS | Valine, leucine and isoleucine degradation | 21/1875 | 48/8465 | 6.73e-04 | 4.51e-03 | 2.76e-03 | 21 |
hsa006404 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa002803 | Colorectum | MSS | Valine, leucine and isoleucine degradation | 21/1875 | 48/8465 | 6.73e-04 | 4.51e-03 | 2.76e-03 | 21 |
hsa006405 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa006406 | Colorectum | FAP | Propanoate metabolism | 15/1404 | 32/8465 | 6.21e-05 | 6.10e-04 | 3.71e-04 | 15 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCCA | SNV | Missense_Mutation | novel | c.1532N>A | p.Gly511Asp | p.G511D | P05165 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A5ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
PCCA | SNV | Missense_Mutation | c.739C>G | p.Gln247Glu | p.Q247E | P05165 | protein_coding | tolerated(0.31) | benign(0.021) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PCCA | SNV | Missense_Mutation | novel | c.2158G>A | p.Glu720Lys | p.E720K | P05165 | protein_coding | tolerated(0.36) | probably_damaging(0.933) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PCCA | insertion | Frame_Shift_Ins | novel | c.151_152insCCAGC | p.Leu51ProfsTer55 | p.L51Pfs*55 | P05165 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PCCA | insertion | Frame_Shift_Ins | novel | c.152_153insACTCAGGAGGCTGAGG | p.Gly52LeufsTer11 | p.G52Lfs*11 | P05165 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PCCA | SNV | Missense_Mutation | novel | c.1349N>T | p.Ser450Leu | p.S450L | P05165 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PCCA | SNV | Missense_Mutation | novel | c.1544N>C | p.His515Pro | p.H515P | P05165 | protein_coding | tolerated(0.36) | possibly_damaging(0.535) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PCCA | SNV | Missense_Mutation | rs747943045 | c.689N>A | p.Arg230His | p.R230H | P05165 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PCCA | SNV | Missense_Mutation | c.1943A>C | p.Lys648Thr | p.K648T | P05165 | protein_coding | tolerated(0.08) | benign(0.13) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
PCCA | SNV | Missense_Mutation | rs368047060 | c.803G>A | p.Arg268His | p.R268H | P05165 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |